Jump to content
Advertisement

Advertisement

IBS News

Showing topics posted by Health Reporter and posted in for the last 365 days.

This stream auto-updates     

  1. Today
  2. Irritable bowel syndrome leading to scurvy from a severely restricted diet. Proc (Bayl Univ Med Cent). 2020 Jul 23;33(4):627-629 Authors: Venkataraman V, Olson KR Abstract A 69-year-old man with irritable bowel syndrome on a restricted diet presented with fatigue, myalgias, extensive bilateral lower-extremity petechiae and ecchymoses, transfusion-refractory anemia, and elevated inflammatory markers. A low serum vitamin C level led to the diagnosis of scurvy. This is the first reported case of vitamin C deficiency and clinical scurvy related to voluntary dietary restriction from irritable bowel syndrome in an adult patient. PMID: 33100549 [PubMed] View the full article
  3. Effect of inulin in the treatment of irritable bowel syndrome with constipation (Review). Exp Ther Med. 2020 Dec;20(6):185 Authors: Bărboi OB, Ciortescu I, Chirilă I, Anton C, Drug V Abstract At present, irritable bowel syndrome (IBS) is a common medical problem all over the world that implies considerable social burden and high costs. Considering the different pathophysiological pathways, unitary management for IBS is not possible. Of the therapeutic approaches that have been proposed so far, only a few have been demonstrated to have beneficial effects in IBS patients. The implication of gut microbiota in IBS is obvious, similarly to the therapeutic effect of pro-/prebiotics, which is reflected by the latest publications. The intake of inulin seems to regulate the bowel peristalsis and colonic transit, the consistency and frequency of the stools, as it changes the composition of gut microbiota. The beneficial effect of inulin in patients with IBS-constipation form (IBS-C) is obvious, but still, more randomized controlled clinical trials involving large samples of patients are needed in order to provide more evidence. PMID: 33101475 [PubMed] View the full article
  4. Yesterday
  5. Constipation up to three times more prevalent in pregnant women Healio The prevalence of constipation among women was two- to threefold higher during pregnancy and for the first few days postpartum, researchers wrote in the British Journal of Obstetrics and Gynecology. “Gastrointestinal function during pregnancy and in postpartum should receive attention because severe constipation may have a substantial impact on the pregnancy experience and may affect the mother’s physical and social heath status and impair the relationship between mother and newborn,” Moona Kuronen, a student at the University of Eastern Finland, and colleagues wrote. View the full article
  6. Kiwifruit Better Tolerated Than Prunes or Psyllium for Chronic Constipation MedPage Today For patients with chronic constipation, green kiwifruit (a.k.a. Chinese gooseberry) was associated with fewer adverse effects and greater patient satisfaction than psyllium or prunes, although all three were effective, according to a randomized trial. In a presentation at the American College of Gastroenterology virtual meeting,Samuel W. Chey, MPH, of the University of Michigan HealthSystem in Ann Arbor, said that while psyllium and prunes are proven treatments for chronic constipation, Asian studies, including one from China, have suggested that fresh kiwi may also mitigate symptoms, especially in an era when people with functional bowel problems are increasingly seeking natural solutions. View the full article
  7. Last week
  8. Cannabis, Probiotics and More: What Works Best for IBS? Michigan Medicine The symptoms for irritable bowel syndrome, or IBS, can range from mildly annoying to severely life-altering. And according to Justin Brandler, M.D., a gastroenterology fellow at Michigan Medicine, the disease truly is a spectrum. “From mapping out every bathroom location on your travel itinerary, to hiding your diarrhea and incapacitating abdominal cramping from your colleagues, IBS can include many different things,” says Brandler. “As the pandemic continues, many patients with IBS have experienced improved symptoms as they stay closer to home. However, others have had to deal with a significant worsening of symptoms due to unexpected uncertainties, like job loss, disrupted child care and social isolation.” Brandler adds that this range in symptoms and severity can be especially challenging for both providers and patients, even outside of a pandemic. But as a physician, he finds this diversity both challenging and rewarding. “In order to properly care for patients with IBS, a healthy blend of art and science is required, as well as a partnership with our patients to develop evidence-based and personalized treatment plans that revolve around a trusting clinician-patient relationship,” he says. View the full article
  9. IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open. 2020 Oct 21;10(10):e041733 Authors: Moayyedi P, MacQueen G, Bernstein CN, Vanner S, Bercik P, Madsen KL, Surette M, Rioux JD, Dieleman LA, Verdú E, de Souza RJ, Otley A, Targownik L, Lavis J, Cunningham J, Marshall DA, Zelinsky S, Fernandes A Abstract INTRODUCTION: Gut microbiome and diet may be important in irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and comorbid psychiatric conditions, but the mechanisms are unclear. We will create a large cohort of patients with IBS, IBD and healthy controls, and follow them over time, collecting dietary and mental health information and biological samples, to assess their gastrointestinal (GI) and psychological symptoms in association with their diet, gut microbiome and metabolome. METHODS AND ANALYSIS: This 5-year observational prospective cohort study is recruiting 8000 participants from 15 Canadian centres. Persons with IBS who are 13 years of age and older or IBD ≥5 years will be recruited. Healthy controls will be recruited from the general public and from friends or relatives of those with IBD or IBS who do not have GI symptoms. Participants answer surveys and provide blood, urine and stool samples annually. Surveys assess disease activity, quality of life, physical pain, lifestyle factors, psychological status and diet. The main outcomes evaluated will be the association between the diet, inflammatory, genetic, microbiome and metabolomic profiles in those with IBD and IBS compared with healthy controls using multivariate logistic regression. We will also compare these profiles in those with active versus quiescent disease and those with and without psychological comorbidity. ETHICS AND DISSEMINATION: Approval has been obtained from the institutional review boards of all centres taking part in the study. We will develop evidence-based knowledge translation initiatives for patients, clinicians and policymakers to disseminate results to relevant stakeholders.Trial registration number: NCT03131414. PMID: 33087380 [PubMed - in process] View the full article
  10. Prevalence and Associated Dietary Factors of Rome IV Functional Gastrointestinal Disorders in Rural Western Honduras. Dig Dis Sci. 2020 Oct 22;: Authors: Norwood DA, Dominguez LB, Paredes AA, Montalvan EE, Rodriguez Murillo A, Dougherty MK, Palsson OS, Dominguez RL, Morgan DR Abstract BACKGROUND: The literature is limited regarding the prevalence of functional gastrointestinal disorders (FGIDs) in Central America, and the role of dietary factors. METHODS: The Rome IV diagnostic questionnaire and National Cancer Institute Diet History questionnaire were administered in one-on-one interviews to a distributed cross section of the general adult population of Western Honduras. Our aim was to estimate prevalence of common FGIDs and symptoms and their relationships to dietary habits. RESULTS: In total, 815 subjects were interviewed, of whom 151 fulfilled criteria for an FGID (18.5%). Gastroduodenal FGIDs were noted in 9.4%, with epigastric pain syndrome (EPS) more common than postprandial distress syndrome, 8.5% versus 1.6%. Among bowel disorders, functional abdominal bloating (FAB) was most prevalent (6.3%), followed by irritable bowel syndrome (3.6%), functional diarrhea (FDr; 3.4%), and functional constipation (1.1%). A significant inverse association was noted between regular bean intake and any FGID (OR 0.41, 95% CI 0.27-0.63), driven by IBS and FDr. Vegetable consumption was associated with lower prevalence of functional diarrhea (OR 0.12; 95% CI 0.04-0.35) and any diarrheal disorder (OR 0.11; 95% CI 0.04-0.31). Subjects with a median daily intake of ≥ 4 corn tortillas had 1.75 (95% CI 1.22-2.50) times the odds of having any FGID. CONCLUSIONS: FGIDs were common in this rural low-resource setting in Central America, with an intriguing distribution of specific FGIDs. EPS and FAB were common, but IBS was not. Local dietary factors were associated with specific FGIDs, suggesting that diet may play a role in global variations of FGIDs. PMID: 33089482 [PubMed - as supplied by publisher] View the full article
  11. Behavioral and Diet Therapies in Integrated Care for Patients with Irritable Bowel Syndrome. Gastroenterology. 2020 Oct 19;: Authors: Chey WD, Keefer L, Whelan K, Gibson PR Abstract Irritable bowel syndrome (IBS) is a common, symptom-based condition that has negative effects on quality of life and costs healthcare systems billions of dollars each year. Until recently, management of IBS has focused on over the counter and prescription medications that reduce symptoms in fewer than half of patients. Patients have increasingly sought natural solutions for their IBS symptoms. However, behavioral techniques and dietary modification can be effective in treatment of IBS. Behavioral interventions include gastrointestinal-focused cognitive behavioral therapy and gut-directed hypnotherapy, to modify interactions between the gut and the brain. In this pathway, benign sensations from the gut induce maladaptive cognitive or affective processes that amplify symptom perception. Symptoms occur in response to cognitive and affective factors that trigger fear of symptoms or lack of acceptance of disease, or from stressors in the external environment. Among the many dietary interventions used to treat patients with IBS, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) is the most commonly recommended by healthcare providers and has the most evidence for efficacy. Patient with IBS who choose to follow the low-FODMAP diet should be aware of its 3 phases: restriction, reintroduction, and personalization. Management of IBS should include an integrated care model, in which behavioral interventions, dietary modification, and medications are considered as equal partners. This approach offers the greatest likelihood for success in management of patients with IBS. PMID: 33091411 [PubMed - as supplied by publisher] View the full article
  12. Functional Constipation and IBS More Common in Pediatric Celiac Disease Clinical Pain Advisor Children with celiac disease are at an increased risk for functional constipation and irritable bowel syndrome (IBS) compared with healthy controls, despite a strict adherence to gluten-free diet, according to study results published in Clinical Gastroenterology and Hepatology. Functional abdominal pain disorders — including functional dyspepsia, IBS, abdominal migraine, and functional abdominal pain not otherwise specified — are more common in children. Previous studies have reported a 5-fold increased risk for celiac disease in patients with IBS, and more than a third of patients with celiac disease present symptoms compatible with IBS. View the full article
  13. Psychiatric symptoms and relationship of disease with stress and traumatic experiences in patients with irritable bowel syndrome. Riv Psichiatr. 2020 Sep-Oct;55(5):292-296 Authors: Torun F, Koç G, Ocak Serın S, Dılek Torun S Abstract AIM: The aim of this study is to evaluate psychiatric symptoms in patients with irritable bowel syndrome (IBS) and investigate the relationship of traumatic life events with the disease. METHODS: Fifty-four patients and fifty healthy controls were included in this study. Psychiatric symptoms were measured with the Symptom Checklist-90-R (SCL-90R), State-Trait Anxiety Inventory (STAI) and sociodemographic information form were used. All scales were applied to both IBS cases and healthy control groups. RESULTS: Somatization, obsessive-compulsive disorder, anger hostility, additional items and total scores of SCL-90-R were higher in the IBS group compared to the control group. Trait anxiety was significantly higher in the IBS group and state anxiety, significantly higher in the control group. In those with a personal history of traumatic events, all subscales and total scores of SCL-90-R were increased significantly. Scores of psychiatric scales, which indicate stressful life events, were significantly higher before the onset of abdominal pain. CONCLUSIONS: Environmental factors that cause considerable emotional distress, such as chronic stress, trauma, and abuse, have been linked to IBS and the severity of symptoms. Therefore, it is important to consider the psychiatric symptoms in the management of IBS. PMID: 33079074 [PubMed - as supplied by publisher] View the full article
  14. Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation? Am J Gastroenterol. 2020 Oct 19;: Authors: Melchior C, Simrén M Abstract There is a clear unmet need for new treatments in irritable bowel syndrome with diarrhea (IBS-D). Ondansetron, an old 5-hydroxy-tryptamine3 antagonist, used for chemotherapy-induced nausea and vomiting and with favorable side effect profile, has shown promising results in previous trials. In this issue, efficacy with a novel bimodal release ondansetron formulation was presented in IBS-D. The bimodal release ondansetron improved stool consistency, presumably by slowing transit time, and tended to improve other IBS symptoms as well. The authors proposed C-reactive protein levels as a tool to select responders because a better response was seen in patients with slightly elevated C-reactive protein levels. Future large-scale studies will determine the role of bimodal release ondansetron in IBS-D with and without low-grade inflammation. PMID: 33079746 [PubMed - as supplied by publisher] View the full article
  15. Biopsychosocial Model and Perceived Constipation Severity According to the Constipation Phenotype. Dig Dis Sci. 2020 Oct 19;: Authors: Bouchoucha M, Fysekidis M, Deutsch D, Bejou B, Sabate JM, Benamouzig R Abstract PURPOSE: Constipation is a frequent complaint of patients with functional bowel disorders. The present study aimed to evaluate the relationship between the perceived constipation severity with demographics, clinical, physiological, and psychological parameters in constipated patients. PATIENTS AND METHODS: Four hundred seven constipated patients were included and had clinical, physiological, and psychological evaluation. The self-reported severity of constipation was analyzed using stepwise linear regression in the total population and within each clinical group. RESULTS: The patients were mainly of female gender (81%) and were 47.4 ± 16.5 years old. They complained of IBS (65%), and 62% had defecation disorders. The depression scale was abnormal in 200 patients (49%). The relationships of the constipation severity varied according to the Rome IV phenotype. In all phenotypes, it was positively associated with bloating severity, and negatively with Bristol stool form. In IBS patients, perceived constipation severity was also associated with abdominal pain severity. CONCLUSION: Our data support the hypothesis that perceived constipation severity is associated with clinical and physiological factors but not demographics and psychological factors. Besides, the relationships of perceived constipation severity with these factors vary according to clinical phenotypes. PMID: 33073331 [PubMed - as supplied by publisher] View the full article
  16. Low FODMAP Diet Is Not Effective in Children with Functional Abdominal Pain: A Randomized Controlled Trial. Ann Nutr Metab. 2020 Oct 19;:1-11 Authors: Boradyn KM, Przybyłowicz KE, Jarocka-Cyrta E Abstract INTRODUCTION: A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) has been shown to reduce symptoms among adult patients and children with irritable bowel syndrome. There are no studies investigating the effectiveness of the low FODMAP diet in pediatric patients with functional abdominal pain (FAP). OBJECTIVE: The study aimed to evaluate the effectiveness of the low FODMAP diet in reducing gastrointestinal symptoms in children with FAP in comparison to the control diet based on the National Institute for Health and Care Excellence (NICE) guidelines. METHODS: Twenty-seven children with diagnosed FAP were randomized to 2 groups. Each group received an intervention: the low FODMAP diet or the diet based on NICE. All food was prepared and delivered by a catering company. Data regarding gastrointestinal symptoms were recorded by participants during the 2-week baseline assessment and 4-week dietary intervention. The frequencies of abdominal pain and stools were reported as a number of events per day. The severity of abdominal pain was assessed using the Wong-Baker FACES Pain Rating Scale. The assessment of stool consistency was based on the Bristol Stool Form Scale. RESULTS: The tendency toward the improvement in abdominal symptoms was noted in the low FODMAP group but without statistical significance. No significant differences in stool consistency were observed in this group. The NICE group experienced significant reduction in abdominal pain intensity and frequency (p < 0.01) and improvement in stool consistency (93% reporting normal stool, p < 0.05). CONCLUSIONS: The results of this pilot study suggest that the low FODMAP diet is not effective in the reduction of symptoms in children with FAP. PMID: 33075788 [PubMed - as supplied by publisher] View the full article
  17. Earlier
  18. Rifaximin significantly improves bloating in IBS-D Healio In a composite of three trials, rifaximin provided a durable and significant improvement in bloating in patients with diarrhea-predominant irritable bowel syndrome as compared with placebo, according to results presented at UEG Week. “A significantly greater percentage of patients receiving rifaximin were durable bloating responders compared to placebo using again the greater than or equal to one-point or the greater than or equal to two-point responder definition,” Brian E. Lacy, MD, PhD, from the Mayo Clinic in Jacksonville, Florida, said during his presentation. Lacy and colleagues identified 1,894 patients with IBS-D and randomly assigned them to rifaximin 550 mg three times daily (n = 952) or placebo for 2 weeks (n = 942) and then a 4-week treatment-free follow-up period to assess patient response. Patients answered a daily and weekly questionnaire on IBS-related bloating and relief from medication to determine their bloating severity during the first and second trial. During the third trial, bloating severity was assessed based on the patient response to questions on their bloating within 24 hours. View the full article
  19. Irritable bowel syndrome: Epidemiology and risk factors in the adult Saudi population of the central region. Niger J Clin Pract. 2020 Oct;23(10):1414-1418 Authors: Aljammaz KI, Alrashed AA, Alzwaid AA Abstract Background: Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disease. The prevalence of IBS is estimated to be 11.2% worldwide and even though it is not a life-threatening condition, it affects the quality of life and results in an economic burden on the healthcare system. According to the Rome III criteria, IBS is described as abdominal pain that improves with defecation and the onset of the pain is associated with a change in stool frequency or consistency that cannot be explained by any biochemical or structural abnormality. Aim: To document the epidemiology of IBS and its associated risk factors in the central region of Saudi Arabia. Materials and Methods: A cross-sectional study conducted in the central region of Saudi Arabia, carried out by distributing an online self-administered semi-structured questionnaire. The questionnaire was distributed online in social media and websites. The sample size was 426 participants with a precision of ± 5% and 95% confidence interval (CI). The questionnaire included demographic characters such as age, gender, occupation, and marital status. The questionnaire also included body mass index (BMI), smoking, family history of IBS, Rome III criteria for diagnosing IBS, and Hospital Anxiety and Depression Scale (HADS) for anxiety and depression. Results: A total of 426 (230 [54%] male and 196 [46%] female) participants were enrolled in the study. According to Rome III criteria, 130 had IBS and the prevalence was 30.5%. Univariate analysis showed that gender, anxiety, depression, and low physical activity are statistically significant variables with symptomatic IBS (P < 0.05). Conclusion: In this study, a high prevalence of IBS in the Central Saudi Arabia population was observed along with the presence of some modifiable risk factors, yet, the sample size was small which shows the need for more studies in this area particularly on the general population. PMID: 33047699 [PubMed - in process] View the full article
  20. Impact of Chronic Constipation on Health-Related Quality of Life and Work Productivity in Japan. J Gastroenterol Hepatol. 2020 Oct 13;: Authors: Tomita T, Kazumori K, Baba K, Zhao X, Chen Y, Miwa H Abstract BACKGROUND AND AIMS: The impact of chronic constipation on health-related quality of life (HRQoL), work productivity and healthcare resource use in Japan is not well understood. This study aimed to evaluate and compare the humanistic burden of respondents with chronic constipation to respondents without chronic constipation (CC), and to respondents with type 2 diabetes mellitus (T2DM), irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD), respectively. METHODS: This cross-sectional study collected demographic and general health data and HRQoL data as measured by the SF-12v2 and EQ-5D health surveys. Health impacts on employment-related activities and indirect costs were measured using the Work Productivity and Activity Impairment (WPAI) questionnaire. Propensity score matching was used to identify a control group without chronic constipation. Multivariate generalized linear models were used to identify potential factors that may impact the outcomes of respondents. RESULTS: 30,001 individuals responded to the Japan National Health and Wellness Survey (NHWS) 2017, whereof 3,373 (11.2%) reported having chronic constipation; 963 were physician-diagnosed. Compared to matched controls, patients with physician-diagnosed chronic constipation had lower mean HRQoL scores and higher mean absenteeism, presenteeism, total WPAI, and indirect costs. Physician-diagnosed chronic constipation was associated with a higher health burden than T2DM, IBS and GERD. CONCLUSIONS: Chronic constipation is associated with a considerable health burden, which is higher compared to T2DM, IBS, and GERD. These results suggest an urgent need for effective treatment of Japanese patients with chronic constipation to improve their quality of life. PMID: 33047825 [PubMed - as supplied by publisher] View the full article
  21. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020 Oct 09;: Authors: Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC Abstract Gastrointestinal symptoms are highly prevalent, but many people who have them will have no organic explanation for their symptoms. Most of these people will be labelled as having a functional gastrointestinal disorder, such as irritable bowel syndrome, functional dyspepsia, or functional constipation. These conditions affect up to 40% of people at any one point in time, and two-thirds of these people will have chronic, fluctuating symptoms. The pathophysiology of functional gastrointestinal disorders is complex, but involves bidirectional dysregulation of gut-brain interaction (via the gut-brain axis), as well as microbial dysbiosis within the gut, altered mucosal immune function, visceral hypersensitivity, and abnormal gastrointestinal motility. Hence, nomenclature refers to the conditions as disorders of gut-brain interaction. Psychological comorbidity is common; however, whether or not this predates, or is driven by, symptoms is not clear. Patients with functional gastrointestinal disorders can feel stigmatised, and often this diagnosis is not communicated effectively by physicians, nor is education provided. Prompt identification and treatment of these conditions is crucial as they have a considerable impact on health-care systems and society as a whole because of repeated consultations, unnecessary investigations and surgeries, prescriptions and over-the-counter medicine use, and impaired health-related quality of life and ability to work. Symptom-based criteria are used to make a diagnosis, with judicious use of limited investigations in some patients. The general principles of treatment are based on a biopsychosocial understanding and involve management of physical symptoms and, if present, psychological comorbidity. In the future, treatment approaches to functional gastrointestinal disorders are likely to become more personalised, based not only on symptoms but also underlying pathophysiology and psychology. PMID: 33049221 [PubMed - as supplied by publisher] View the full article
  22. Health Reporter

    Pubmed-Irritable bowel syndrome

    Irritable bowel syndrome. Lancet. 2020 Oct 09;: Authors: Ford AC, Sperber AD, Corsetti M, Camilleri M Abstract Irritable bowel syndrome is a functional gastrointestinal disorder with symptoms including abdominal pain associated with a change in stool form or frequency. The condition affects between 5% and 10% of otherwise healthy individuals at any one point in time and, in most people, runs a relapsing and remitting course. The best described risk factor is acute enteric infection, but irritable bowel syndrome is also more common in people with psychological comorbidity and in young adult women than in the rest of the general population. The pathophysiology of irritable bowel syndrome is incompletely understood, but it is well established that there is disordered communication between the gut and the brain, leading to motility disturbances, visceral hypersensitivity, and altered CNS processing. Other less reproducible mechanisms might include genetic associations, alterations in gastrointestinal microbiota, and disturbances in mucosal and immune function. In most people, diagnosis can be made on the basis of clinical history with limited and judicious use of investigations, unless alarm symptoms such as weight loss or rectal bleeding are present, or there is a family history of inflammatory bowel disease or coeliac disease. Once the diagnosis is made, an empathetic approach is key and can improve quality of life and symptoms, and reduce health-care expenditure. The mainstays of treatment include patient education about the condition, dietary changes, soluble fibre, and antispasmodic drugs. Other treatments tend to be reserved for people with severe symptoms and include central neuromodulators, intestinal secretagogues, drugs acting on opioid or 5-HT receptors, or minimally absorbed antibiotics (all of which are selected according to predominant bowel habit), as well as psychological therapies. Increased understanding of the pathophysiology of irritable bowel syndrome in the past 10 years has led to a healthy pipeline of novel drugs in development. PMID: 33049223 [PubMed - as supplied by publisher] View the full article
  23. Asthma, Food Sensitivity, and Irritable Bowel Syndrome MedicineNet Teens who had asthma and food hypersensitivity when they were younger are at increased risk of irritable bowel syndrome (IBS), researchers report. For the study, the investigators examined the health of 2,770 children from birth to age 16. Kids with IBS at age 16 were more likely to have had asthma at age 12 (about 11% versus 7%). In addition, the researchers found that 16-year-olds with IBS were more likely to have had food hypersensitivity at age 12 (41% versus 29%). Asthma, food hypersensitivity and eczema (a condition that makes your skin red and itchy) were all associated with an increased risk of concurrent IBS at age 16, the findings showed. "The associations found in this large study suggest there's a shared pathophysiology between common allergy-related diseases and adolescent irritable bowel syndrome," said study leader Jessica Sjölund, of the Institute of Medicine at the University of Gothenburg, in Sweden. View the full article
  24. RT @DrKateTomasino: Just over a week until Dr. Megan Petrik and I present on #gastropsych and Brain-Gut psychotherapies for #DGBI at APA's CE Institute series on Th 10/22. You can register here: https://apa.content.online/catalog/product.xhtml?eid=23517 For other great CE on #gastropsych check out @RomeGastroPsych's offerings! (Feed generated with FetchRSS) View the full article
  25. This infographic summary of #IBS by @alex_ford12399 is a true work of art! Extraordinary to cover full diagnostic criteria & subtyping, pathophysiology, risk factors & their role in symptom severity & detailed medical management guidance in a single easy-to-understand image!: https://twitter.com/TheLancet/status/1315620201535361024 (Feed generated with FetchRSS) View the full article
  26. How a Faecal Transplant Changed My Life VICE UK While it could help to treat IBS and potentially even alcoholism, doctors warn patients to leave the procedure to medical professionals. The human microbiome is a beautiful thing. Recent studies have confirmed that the trillions of microorganisms living in our gut play a vital role in our physical and mental health – and while the research field is new, it’s also promising, because unlocking the secrets to a healthy microbiome could help us to treat conditions ranging from Irritable Bowel Syndrome (IBS) to potentially even alcoholism. View the full article
  27. Study Probes Links in Asthma, Food Sensitivity and Irritable Bowel Syndrome - U.S. News & World Report Teens who had asthma and food hypersensitivity when they were younger are at increased risk of irritable bowel syndrome (IBS), researchers report. For the study, the investigators examined the health of 2,770 children from birth to age 16. Kids with IBS at age 16 were more likely to have had asthma at age 12 (about 11% versus 7%). In addition, the researchers found that 16-year-olds with IBS were more likely to have had food hypersensitivity at age 12 (41% versus 29%). View the full article
  28. Papers to-read in the special issue on #PsychoGastroenterology in @Children_MDPI. Mothers with #IBS feel guilt about how IBS impacts children, worry that children will develop IBS, and are on high alert for children’s health https://www.mdpi.com/2227-9067/7/8/93 (Feed generated with FetchRSS) View the full article
  29. Saying YES to October means saying yes to all things warm & comforting and for us, that means a creamy bowl of Low FODMAP Tomato Basil Soup with Gluten Free Croutons.🥣 ⁠https://www.fodyfoods.com/blogs/low-fodmap-recipes/easy-low-fodmap-tomato-basil-soup-with-gluten-free-croutons @SCHARglutenfree #Fall #October #Soup #Recipes (Feed generated with FetchRSS) View the full article
  1. Load more activity
×
×
  • Create New...